Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/54661| Title: | Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain |
| Authors: | |
| Filiation: | Hospital Universitario de Fuenlabrada. Servicio de Aparato Digestivo |
| Keywords: | |
| Mesh: | |
| Decs: | |
| Issue Date: | 2022 |
| Publisher: | SAGE Publications |
| Citation: | Argüelles-Arias F, Bermejo F, Borrás-Blasco J, Domènech E, Sicilia B, Huguet JM, de Arellano AR, Valentine WJ, Hunt B. Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain. Therap Adv Gastroenterol. 2022 May 9;15:17562848221086131. doi: 10.1177/17562848221086131. PMID: 35574429; PMCID: PMC9092579. |
| Abstract: | Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). |
| PMID: | 35574429 |
| URI: | https://hdl.handle.net/20.500.12530/54661 |
| Rights: | info:eu-repo/semantics/openAccess Atribución-NoComercial-CompartirIgual 3.0 España |
| ISSN: | 1756-283X |
| Appears in Collections: | Hospitales > H. U. de Fuenlabrada > Artículos |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 17562848221086131.pdf | 146.69 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
